drugset
drugset / Trial / NCT04282746

A Study of Sublingually Administered (S)-Ketamine Oral Solution in Healthy Participants

NCT04282746 ↗

Phase 1 Completed 17 enrolled Janssen Research & Development, LLC
NaSequentialOpen-labelOther

Summary

The purpose of this study is to characterize the plasma pharmacokinetic (PK) profile following the single ascending dose (SAD) levels of an (S)-ketamine oral solution for sublingual administration in healthy participants.

Timeline

Start
2020-02-18
Primary completion
2020-08-11
Completion
2020-08-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Esketamine Other / unclassified — Other

Indications

No indication recorded.